Zeltiq Aesthetics Inc. (ZLTQ) Shares Up 2.1%
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ)’s share price shot up 2.1% during trading on Friday . The stock traded as high as $38.57 and last traded at $37.78, with a volume of 849,379 shares trading hands. The stock had previously closed at $36.99.
Several research firms have commented on ZLTQ. Leerink Swann reiterated an “outperform” rating and set a $48.00 price objective (up previously from $43.00) on shares of Zeltiq Aesthetics in a research report on Thursday. Zacks Investment Research upgraded shares of Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a research report on Friday. Maxim Group increased their price objective on shares of Zeltiq Aesthetics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Brean Capital set a $39.00 price objective on shares of Zeltiq Aesthetics and gave the company a “buy” rating in a research report on Tuesday, August 9th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating and set a $35.00 price objective (up previously from $27.00) on shares of Zeltiq Aesthetics in a research report on Tuesday, August 9th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $38.33.
The firm’s 50 day moving average price is $31.49 and its 200 day moving average price is $27.26. The company has a market capitalization of $1.50 billion and a P/E ratio of 56.90.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.07. The business had revenue of $89.50 million for the quarter, compared to the consensus estimate of $79.68 million. During the same period in the previous year, the company earned $0.03 EPS. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. Equities research analysts forecast that Zeltiq Aesthetics Inc. will post ($0.07) earnings per share for the current fiscal year.
In other Zeltiq Aesthetics news, VP Bradley Hauser sold 3,000 shares of the company’s stock in a transaction on Monday, July 11th. The shares were sold at an average price of $30.02, for a total transaction of $90,060.00. Following the completion of the transaction, the vice president now directly owns 47,184 shares in the company, valued at $1,416,463.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keith J. Sullivan sold 8,000 shares of the company’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $30.02, for a total transaction of $240,160.00. Following the transaction, the insider now owns 77,922 shares of the company’s stock, valued at $2,339,218.44. The disclosure for this sale can be found here.
Other institutional investors recently bought and sold shares of the company. New York State Common Retirement Fund boosted its position in Zeltiq Aesthetics by 4.3% in the fourth quarter. New York State Common Retirement Fund now owns 41,532 shares of the company’s stock worth $1,185,000 after buying an additional 1,700 shares in the last quarter. Trexquant Investment LP acquired a new stake in Zeltiq Aesthetics during the fourth quarter worth about $1,640,000. Finally, Wells Fargo & Company MN raised its stake in Zeltiq Aesthetics by 765.2% in the fourth quarter. Wells Fargo & Company MN now owns 404,376 shares of the company’s stock worth $11,537,000 after buying an additional 357,636 shares during the last quarter.
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.